Comparative Pharmacology
Head-to-head clinical analysis: LIQUAEMIN LOCK FLUSH versus PANWARFIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIQUAEMIN LOCK FLUSH versus PANWARFIN.
LIQUAEMIN LOCK FLUSH vs PANWARFIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin potentiates the activity of antithrombin III, thereby inactivating thrombin (factor IIa) and activated factor X (Xa), and preventing fibrin clot formation. It also inhibits factors IXa, XIa, and XIIa.
Anticoagulant that inhibits vitamin K epoxide reductase, thereby decreasing hepatic synthesis of vitamin K-dependent coagulation factors II, VII, IX, and X.
10-100 units/mL solution; flush intermittent intravenous catheters after each use with 1-5 mL; for central venous catheters, use 2-3 mL of 10 units/mL solution; for peripheral catheters, use 1-2 mL of 10 units/mL solution.
5 mg orally once daily, adjusted to maintain INR 2-3.
None Documented
None Documented
1-2 hours (dose-dependent; prolonged with higher doses, renal impairment, or in elderly).
Terminal elimination half-life is 20-60 hours (mean ~40 hours). Clinically, the longer half-life allows for once-daily dosing and steady-state is achieved in 5-7 days; anticoagulant effect may persist for 2-5 days after discontinuation due to depletion of vitamin K-dependent clotting factors.
Renal (predominantly via reticuloendothelial system and liver metabolism; unchanged drug excreted in urine).
Primarily renal as inactive metabolites; 60-92% of a dose is excreted in urine, with about 50% as the 7-hydroxywarfarin metabolite and the remainder as other metabolites. Biliary/fecal elimination accounts for approximately 10-20%.
Category C
Category C
Anticoagulant
Anticoagulant